Kelun Pharmaceutical
科伦药业
Executive Summary
Kelun Pharmaceutical is a major Chinese pharmaceutical company listed on Shenzhen Stock Exchange, headquartered in Chengdu with clear BIOSECURE status. The company has historically been active in both generic drugs and innovative biologics, with particular strength in infusion solutions and oncology therapeutics. Kelun has demonstrated deal-making appetite through previous partnerships and licensing arrangements, making it a viable target for US pharma BD teams seeking China exposure without regulatory risk.
Structure: As a Shenzhen-listed Chinese pharmaceutical company, Kelun likely operates through a standard domestic corporate structure without VIE complications, simplifying due diligence for US partners. The company's clear BIOSECURE status suggests a straightforward corporate structure without concerning ownership layers or problematic affiliations.
Latest Financials
Revenue: 16788775173, Net Profit: 2470927259. Source: East Money (002422)
Period: 2024-09-30 | Source: eastmoney
Ownership & Shareholder Structure
Kelun Pharmaceutical → Kelun-Biotech
Kelun Pharmaceutical controls Kelun-Biotech, the innovative drug discovery arm that licensed 7 ADC targets to Merck for $9.4B+.
Corporate Events
科伦药业：关于公司布瑞哌唑口溶膜获得药品注册批准的公告
CNINFO announcement for Kelun Pharmaceutical (002422.SZ)
科伦药业：关于公司注射用阿立哌唑获得药品注册批准的公告
CNINFO announcement for Kelun Pharmaceutical (002422.SZ)
科伦药业：关于子公司核心产品芦康沙妥珠单抗(sac-TMT)于2025年欧洲肺癌大会上公布的研究成果的公告
CNINFO announcement for Kelun Pharmaceutical (002422.SZ)
科伦药业：关于子公司SKB575新药临床试验申请获国家药品监督管理局批准的公告
CNINFO announcement for Kelun Pharmaceutical (002422.SZ)
科伦药业：2026年度第二期科技创新债券发行结果的公告
CNINFO announcement for Kelun Pharmaceutical (002422.SZ)
Kelun Pharmaceutical Financial Report
Revenue: 16788775173, Net Profit: 2470927259. Source: East Money (002422)
Clinical Trials(50 total)
10
Phase 2
8
Phase 1
2
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07459998 | SKB103 for injection monotherapy | Ph.1, Ph.2 | NOT YET RECRUITING | 277 |
| NCT07380386 | SKB105 for injection Monotherapy | Ph.1, Ph.2 | NOT YET RECRUITING | 256 |
| NCT07448922 | SKB518 for injection, Carboplatin (AUC 5), Bevacizumab, SKB518 for injection | Ph.2 | NOT YET RECRUITING | 290 |
| NCT07474545 | KL0011034 injection, Placebo, Etomidate Injectable Emulsion | Ph.1 | NOT YET RECRUITING | 76 |
| NCT07308106 | SKB571 for injection | Ph.2 | NOT YET RECRUITING | 60 |
| NCT07348861 | Sacituzumab tirumotecan plus Iparomlimab | Ph.2 | NOT YET RECRUITING | 25 |
| NCT07329322 | Sacituzumab Tirumotecan, Osimertinib | Ph.2 | NOT YET RECRUITING | 60 |
| NCT07230405 | SKB571 for injection | Ph.2 | RECRUITING | 190 |
| NCT07324629 | Sacituzumab tirumotecan | Ph.2 | NOT YET RECRUITING | 30 |
| NCT07341100 | SKB264, Clarithromycin | Ph.2 | NOT YET RECRUITING | 20 |
| NCT07240675 | pramipexole hydrochloride sustained-release tablets, KLA478, placebo | Ph.1 | RECRUITING | 40 |
| NCT07054242 | Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab | Ph.2 | NOT YET RECRUITING | 52 |
| NCT07179783 | Sacituzumab Tirumotecan, Tagitanlimab | Ph.2 | RECRUITING | 28 |
| NCT07171034 | KLA318-2 Nanocrystal Injection, Celebrex Capsule | Ph.1 | RECRUITING | 48 |
| NCT07019675 | SKB518, Tislelizumab, Carboplatin | Ph.2 | RECRUITING | 192 |
| NCT07087197 | SKB107 for injection | Ph.1 | RECRUITING | 90 |
| NCT07143318 | KLA578-1 for injection, Etopcoxib Tablets | Ph.1 | RECRUITING | 48 |
| NCT07030790 | KLA480 injection, Placebo | Ph.1 | RECRUITING | 20 |
| NCT06826040 | SKB445 for injection | Ph.1 | RECRUITING | 126 |
| NCT06725381 | SKB571 | Ph.1 | RECRUITING | 138 |
Showing 20 of 50 trials
Top Publications (by citations)
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, Trinh D, Hebbert A, Smith CR, Kulyk S, Lawson JD, He L, Hover LD, Fernandez-Banet J, Hallin J, Vanderpool D, Briere DM, Blaj A, Marx MA, Rodon J, Offin M, Arbour KC, Johnson ML, Kwiatkowski DJ, Jänne PA, Haddox CL, Papadopoulos KP, Henry JT, Leventakos K, Christensen JG, Shazer R, Olson P.
Marine Natural Products in Clinical Use.
Haque N, Parveen S, Tang T, Wei J, Huang Z.
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, Long H, Xu M, Ji Y, Xie J, Tan Y, Zhao X, Song H.
Trop2-targeted therapies in solid tumors: advances and future directions.
Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, Xing D, Yan S, Zhang M.
Development of antibody-drug conjugates in cancer: Overview and prospects.
Ruan DY, Wu HX, Meng Q, Xu RH.
Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH, Bagheri N, Meyfour A, Jafari A, Jahandideh S, Gharibi T, Amirkhani Z, Delam H, Mashatan N, Shahsavarani H, Abdollahpour-Alitappeh M.
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours.
Zhang J, Liu R, Gao S, Li W, Chen Y, Meng Y, Liu C, Jin W, Wu J, Wang Y, Hao Y, Yi S, Qing Y, Ge J, Hu X.
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J, Rodriguez E, Maitland ML, Tsai FY, Socinski MA, Berlin JD, Thomas JS, Al Baghdadi T, Wang IM, Guo C, Golmakani M, Clark LN, Gazdoiu M, Li M, Tolcher AW.
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E.
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin Y, Xu H, Yu G, Mi Y, Fan Y, Wainberg ZA, Wang X, Su C, Yu Q, Lai S, Sun L, Zhuang W, Wang X, Yang J, Li Y, Ge J, Li J, Zhang L, Fang W.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating no current regulatory restrictions for US partnerships
Key Exposures:
- •Potential future designation risk given evolving US-China regulatory landscape
- •Supply chain dependencies on Chinese manufacturing
Mitigation: Company appears to have maintained clean regulatory status, though specific mitigation strategies unknown due to limited recent event data
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity data available, suggesting need for direct engagement to assess current partnership interests
Approach: US BD teams should approach with standard China partnership protocols, focusing on specific therapeutic areas of mutual interest while leveraging the company's clear regulatory status
Red Flags
- ⚠Limited transparency in recent corporate activities and pipeline updates
- ⚠Lack of publicly available subsidiary and management information may indicate disclosure gaps
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 50
- Publications
- 10
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (10 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.